Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche Grants License For Eye Disease Drug

by Lisa M. Jarvis
August 12, 2013 | A version of this story appeared in Volume 91, Issue 32

Roche and the Medicines Patent Pool have inked a supply agreement for Valcyte, an oral treatment for cytomegalovirus, a viral infection that can cause blindness and affects roughly one in 10 people living with HIV in low- and middle-income countries. Medicines Patent Pool is a United Nations-backed mechanism that lowers HIV drug prices by making patent licenses available to generic drug firms. Under the pact, Valcyte will be available at up to a 90% discount in 138 developing and emerging countries, the partners say. As part of the deal, Roche will also provide a license for the HIV medication saquinavir if the need arises.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.